What is the recommended therapy for toxoplasmosis, including dosing, duration, and alternatives for pregnancy, sulfa allergy, and immunocompromised patients?

Toxoplasmosis Therapy

The standard treatment for toxoplasmosis is pyrimethamine plus sulfadiazine plus leucovorin (folinic acid), with specific modifications required for pregnancy, sulfa allergy, and immunocompromised patients. 1

Standard Treatment Regimen

Immunocompetent Adults and HIV-Infected Patients with CNS/Systemic Disease

Pyrimethamine + Sulfadiazine + Leucovorin is the preferred regimen for active toxoplasmosis:

• Pyrimethamine: Loading dose of 200 mg, then 50-75 mg daily (or 2 mg/kg/day for 3 days, then 1 mg/kg/day in children) 1
• Sulfadiazine: 1-1.5 g four times daily in adults (25-50 mg/kg/dose four times daily in children) 1
• Leucovorin (folinic acid): 10-25 mg daily to prevent bone marrow suppression 1
• Duration: Minimum 6 weeks for acute therapy, assuming clinical and radiological improvement 1

Critical monitoring requirement: Complete blood count weekly during daily pyrimethamine therapy, then monthly during less frequent dosing, as pyrimethamine causes reversible bone marrow suppression (neutropenia, anemia, thrombocytopenia) 1. Continue leucovorin for 1 week after stopping pyrimethamine due to its long half-life 1.

Treatment During Pregnancy

Maternal Infection Before 18 Weeks Gestation

Spiramycin monotherapy is recommended when fetal infection is not confirmed:

• Spiramycin: 1 g (3 million IU) orally three times daily (total 3 g or 9 million IU daily) 2
• Continue until delivery if amniotic fluid PCR is negative and fetal ultrasound shows no abnormalities 2
• Available in the United States only through FDA Investigational New Drug process (telephone: 301-796-1600) 2
• Not teratogenic and reduces vertical transmission risk 2, 3

Maternal Infection at or After 18 Weeks OR Confirmed Fetal Infection

Switch to pyrimethamine + sulfadiazine + folinic acid when:

• Maternal infection acquired at ≥18 weeks gestation 2
• Positive amniotic fluid PCR for Toxoplasma gondii 2
• Abnormal fetal ultrasound suggestive of congenital toxoplasmosis (hydrocephalus, intracranial calcifications, ventricular dilation) 2, 4

Dosing: Same as standard adult regimen above, continued until delivery 2

Meta-analysis evidence: Treatment reduces infection risk (RR = 0.34) and clinical manifestations (RR = 0.30), with triple therapy showing more consistent results (RR = 0.22) than spiramycin alone (RR = 0.54) 3

Timing Considerations for Amniocentesis

• Do not perform before 18 weeks gestation 4
• Wait minimum 4 weeks after suspected maternal infection to reduce false-negatives 4

Congenital Toxoplasmosis in Newborns

Pyrimethamine + Sulfadiazine + Leucovorin for 12 months:

• Pyrimethamine: Loading dose 2 mg/kg/day for 2 days, then 1 mg/kg/day for 2-6 months, followed by 1 mg/kg three times weekly 1
• Sulfadiazine: 50 mg/kg/dose twice daily 1
• Leucovorin: 10-25 mg daily 1
• Duration: Full 12 months for moderate-to-severe disease and HIV-infected infants 1

For mild congenital toxoplasmosis in HIV-negative infants only: Some experts alternate pyrimethamine/sulfadiazine/leucovorin monthly with spiramycin (50 mg/kg orally twice daily) from months 7-12, but this is NOT recommended for severe disease or HIV-infected children 1

Sulfa Allergy Alternatives

When sulfonamide hypersensitivity occurs, substitute clindamycin for sulfadiazine:

• Clindamycin: 5.0-7.5 mg/kg orally four times daily (maximum 600 mg/dose) 1
• Continue with pyrimethamine + leucovorin 1
• Monitor for: Fever, rash, gastrointestinal symptoms including pseudomembranous colitis, and hepatotoxicity 1

Alternative options (less studied in children):

• Azithromycin: 900-1,200 mg/day in adults with pyrimethamine and leucovorin 1
• Atovaquone: 1,500 mg orally twice daily with meals, plus pyrimethamine and leucovorin (adult dosing) 1
• Trimethoprim-sulfamethoxazole: 5 mg/kg trimethoprim plus 25 mg/kg sulfamethoxazole IV or orally twice daily (contains sulfa, so only if different sulfa allergy profile) 1

Immunocompromised Patients (HIV, Transplant, Hematologic Malignancies)

Prophylaxis Strategy

Trimethoprim-sulfamethoxazole is first-line prophylaxis for seropositive patients:

• Continue for minimum 6 months post-transplant 5
• Extend during treatment-induced immunosuppression or severe CD4 lymphopenia 5
• Prophylaxis can fail, so combine with weekly blood PCR screening in high-risk allogeneic HSCT recipients 5

Pre-emptive Treatment Based on PCR Monitoring

In seropositive allogeneic HSCT recipients, perform weekly quantitative PCR:

• If positive PCR detected, start treatment immediately with trimethoprim-sulfamethoxazole, pyrimethamine-sulfadiazine, or pyrimethamine-clindamycin 5
• Obtain second PCR sample 5
• If second PCR negative, use clinical judgment to continue therapy or restart prophylaxis 5
• Continue treatment until minimum two negative PCRs for infection, or at least 6 weeks for disease 5

Critical caveat: PCR in blood can be negative even with active toxoplasma disease, so maintain high clinical suspicion 5

Treatment Duration

• Acute therapy: Minimum 6 weeks, longer if extensive disease or poor response 1
• Mortality risk: Particularly high in transplant recipients with organ involvement 5

Ocular Toxoplasmosis

For immunocompromised patients with multifocal toxoplasma retinochoroiditis:

• Intravitreal clindamycin may serve as adjunctive therapy or monotherapy when systemic treatment not tolerated 6
• Aqueous humor PCR essential for diagnosis in atypical presentations 6
• Spiramycin monotherapy shows shorter healing time (64 days vs 88 days) and fewer side effects compared to sulfadiazine/pyrimethamine for ocular disease 7

Common Pitfalls and Monitoring

Drug Toxicities to Monitor

Pyrimethamine:

• Reversible bone marrow suppression (neutropenia, anemia, thrombocytopenia) 1
• Rash including Stevens-Johnson syndrome 1
• Always coadminister leucovorin and continue 1 week after stopping pyrimethamine 1

Sulfadiazine:

• Rash, fever, leukopenia, hepatitis 1
• Gastrointestinal symptoms (nausea, vomiting, diarrhea) 1
• Crystalluria (ensure adequate hydration) 1

Special Populations

HIV-infected pregnant women with symptomatic toxoplasmosis:

• Strongly consider empiric therapy of newborn regardless of maternal treatment 1

Immunosuppressed or HIV-positive women:

• Screen for toxoplasmosis due to reactivation risk and toxoplasmosis encephalitis 4

Women with acute infection planning pregnancy:

• Wait 6 months before attempting conception 4